Novartis under pressure after clinical and pipeline setbacks
Report says Novartis faced increasing pressure following a series of clinical and pipeline setbacks in the second half of 2026, with a major shareholder calling for board changes. Most recent setback cited as September 8 in the Phase III HARBOR study.